ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
Jan 26, 2023 13:16 JST
Source:
Prenetics Global Limited
Cantor Fitzgerald Initiates Coverage on Prenetics with "Overweight" Rating
Target Price at USD7.00
HONG KONG, Jan 26, 2023 - (ACN Newswire) - It is reported that Cantor Fitzgerald initiated coverage on Prenetics Global (PRE.US) with "Overweight" rating and target price at USD7.00.
Cantor Fitzgerald holds a favorable view of the consumer and clinical testing markets, with Prenetics' focus on diagnostic and preventive testing coupled with personalized and primary care facilities to address a global market opportunity of over $200 billion. In addition, Cantor Fitzgerald believes its commercialization strategy in rolling out tests both via B2C and B2B in the future, depending on which avenue will result in the broadest adoption with the lowest amount of operating expenses, is unique and sound. Prenetics looks to add new tests to its platform through acquisitions and partnerships, resulting in faster time to market and a comprehensive healthcare ecosystem in a not-so-distant future.
Meanwhile, with Prenetics' ecosystem coming together and being able to uniquely demonstrate profitability given its lower operating expenses and R&D expenses relative to peers, Cantor Fitzgerald thinks Prenetics' shares are also attractively valued.
In the near term, Prenetics will focus on Hong Kong, Southeast Asia and the UK, where the company has strong leadership teams in place and benefits from little to no competition, most notably in Asia.
Source: Prenetics Global Limited
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Honda Announces CUV e: and ICON e: Electric Personal Commuters in Indonesia
Oct 09, 2024 17:46 JST
Mitsubishi Power Completes Landmark 5,300MW Combined Cycle Power Plant Project in Thailand
Oct 09, 2024 17:16 JST
Honda Introduces Next-generation Technologies for Honda 0 Series Models at Honda 0 Tech Meeting 2024
Oct 09, 2024 17:03 JST
Toyota to Exhibit at Japan Mobility Show Bizweek 2024
Oct 09, 2024 14:48 JST
Fujitsu leverages data to secure stable and efficient power supply for Kansai Transmission and Distribution
Oct 09, 2024 11:00 JST
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
Oct 08, 2024 14:00 JST
JCB and Nuvei expand global partnership in APAC
Oct 08, 2024 12:00 JST
JCB to offer Google Pay(TM) in Japan
Oct 07, 2024 11:00 JST
Fujitsu highlights technologies to realize its vision of AI as a trusted assistant at CEATEC 2024
Oct 04, 2024 11:03 JST
Toyota to Invest $500 Million in Joby Aviation
Oct 03, 2024 15:59 JST
Fujitsu and Supermicro announce strategic collaboration to develop green AI computing technology and liquid-cooled datacenter solutions
Oct 03, 2024 09:38 JST
Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Oct 02, 2024 11:28 JST
IOWN All-Photonics Network with Optical Fiber Sensing Functions Achieves Wide-Area Traffic Flow Monitoring
Oct 01, 2024 17:44 JST
Release of Mazda Integrated Report 2024
Oct 01, 2024 10:56 JST
DENSO and ROHM Agree to Start Consideration of Strategic Partnership in the Semiconductor Field
Oct 01, 2024 09:27 JST
Olympus Launches VISERA S, a New Imaging Platform
Sep 30, 2024 15:00 JST
Fujitsu launches "Takane" - A large language model for enterprises offering the highest Japanese language proficiency in the world
Sep 30, 2024 14:05 JST
DENSO Announces Changes of Executive Responsibility and Executive Officers
Sep 30, 2024 13:22 JST
Mitsubishi Corporation: JOGMEC Commissioned Feasibility Study for Overseas CCS Value Chain
Sep 30, 2024 11:38 JST
Mazda Production and Sales Results for August 2024
Sep 27, 2024 17:20 JST
More Latest Release >>
Related Release
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture "Insighta" for Breakthrough Multi-Cancer Early Detection Screening
June 26 2023 09:37 JST
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results, New Business Strategy Focused on Precision Oncology
March 14 2023 22:05 JST
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
March 04 2023 15:40 JST
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
January 11 2023 11:19 JST
Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics
December 16 2022 19:57 JST
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
November 30 2022 22:43 JST
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
November 10 2022 21:36 JST
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
September 09 2022 21:54 JST
More Press release >>